StockData
FibroBiologics, Inc. logo

FibroBiologics, Inc. (FBLG) stock

FBLGNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 2/30
$0.84−0.06 (-6.72%)

Close on Nov 18, 2026Market cap $5.59MP/E –Yield –

FibroBiologics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

FibroBiologics's operating income for the twelve months ending Jun 30, 2026 was -$16.73M. For fiscal 2025 it was -$16.65M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$16.65M–
FY2024Dec 31, 2024-$13.74M–
FY2023Dec 31, 2023-$8.89M–
FY2022Dec 31, 2022-$4.47M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$4.03M–
Q1 FY2026Mar 31, 2026-$5.07M–
Q4 FY2025Dec 31, 2025-$2.59M–
Q3 FY2025Sep 30, 2025-$5.04M–
Q2 FY2025Jun 30, 2025-$4.49M–
Q1 FY2025Mar 31, 2025-$4.53M–
Q4 FY2024Dec 31, 2024-$3.71M–
Q3 FY2024Sep 30, 2024-$3.35M–
Q2 FY2024Jun 30, 2024-$3.22M–
Q1 FY2024Mar 31, 2024-$3.45M–
Q4 FY2023Dec 31, 2023-$2.48M–
Q3 FY2023Sep 30, 2023-$2.05M–
Q2 FY2023Jun 30, 2023-$2.09M–
Q1 FY2023Mar 31, 2023-$2.27M–

More FibroBiologics figures

See a number that looks wrong?